Viewing Study NCT05081336



Ignite Creation Date: 2024-05-06 @ 4:45 PM
Last Modification Date: 2024-10-26 @ 2:15 PM
Study NCT ID: NCT05081336
Status: UNKNOWN
Last Update Posted: 2021-10-25
First Post: 2021-10-05

Brief Title: Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events Republic of Srpska Registry
Sponsor: University Clinical Centre of Republic of Srpska
Organization: University Clinical Centre of Republic of Srpska

Study Overview

Official Title: Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events Republic of Srpska Registry
Status: UNKNOWN
Status Verified Date: 2021-10
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: RS-ACS
Brief Summary: Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol LDL-C reduces cardiovascular adverse events following acute coronary syndrome ACS However the data coming from the real-world setting are limited Therefore the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS

Patients with ACS will be followed for mortality and major events for at least 1 year Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None